ProCE Banner Activity

CENTAURUS: Randomized Study of Daratumumab Dosing in Intermediate- or High-Risk Smoldering Multiple Myeloma

Slideset Download
Conference Coverage
Daratumumab monotherapy demonstrated clinical activity and a favorable safety profile in patients with intermediate- and high-risk smoldering multiple myeloma.

Released: December 15, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology